Can RNR be a Therapeutic Target in Cancer Treatment?
Given its critical role in DNA synthesis and cell proliferation, RNR is an attractive target for cancer therapy. Inhibitors of RNR, such as hydroxyurea and gemcitabine, are already used in clinical settings. Researchers are continually exploring new RNR inhibitors with better specificity and fewer side effects. Targeting the regulatory pathways of RNR, such as interactions with p53 or c-Myc, also holds promise in developing novel cancer therapies.
